Trial Profile
Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Biomarker; Therapeutic Use
- 14 Apr 2019 Status changed from active, no longer recruiting to completed.
- 29 Oct 2016 Planned End Date changed from 1 Jul 2015 to 1 Dec 2016.
- 29 Oct 2016 Status changed from recruiting to active, no longer recruiting.